BSX

SEC source: 0001225208-25-000205 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,578,326

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000206 · doc4.xml · derivative · entry 4

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,430 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000206 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,606

SEC source: 0001225208-25-000206 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F2 · balance_after: Includes shares acquired on June 30, 2024 under the Company's Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-25-000204 · doc4.xml · derivative · entry 4

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,907 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000204 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,600

SEC source: 0001225208-25-000204 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,025

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000203 · doc4.xml · derivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,940 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000203 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,502

SEC source: 0001225208-25-000203 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000202 · doc4.xml · derivative · entry 3

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,456 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000202 · doc4.xml · nonDerivative · entry 2

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,875

SEC source: 0001225208-25-000202 · doc4.xml · nonDerivative · entry 1

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,866

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000201 · doc4.xml · derivative · entry 4

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,901 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000201 · doc4.xml · nonDerivative · entry 2

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 233,610

SEC source: 0001225208-25-000201 · doc4.xml · nonDerivative · entry 1

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 238,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-001683 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,148

F1 · kind: This transaction was inadvertently effected by a broker through a broker managed account, without any instruction from or knowledge of the reporting person.

SEC source: 0001225208-25-001683 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,168

F1 · kind: This transaction was inadvertently effected by a broker through a broker managed account, without any instruction from or knowledge of the reporting person.

SEC source: 0001225208-24-010528 · doc4.xml · derivative · entry 5

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,183

Underlying: Common Stock · 1,197 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-24-010528 · doc4.xml · derivative · entry 4

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,066 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-010528 · doc4.xml · nonDerivative · entry 3

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,308

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-010528 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,291

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-010528 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,094

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-010326 · doc4.xml · nonDerivative · entry 1

Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,957

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $90.6202 to $90.6538, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Includes shares acquired on June 30, 2024 under the Company's Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-24-010220 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,118

SEC source: 0001225208-24-010259 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 201,478

SEC source: 0001225208-24-010179 · doc4.xml · derivative · entry 6

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,706

Underlying: Common Stock · 3,177 shares

Expires 2026-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-010179 · doc4.xml · derivative · entry 5

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,036

Underlying: Common Stock · 1,009 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-010179 · doc4.xml · nonDerivative · entry 3

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 978

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $88.76 to $89.74 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-010179 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,988

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

SEC source: 0001225208-24-010179 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

SEC source: 0001225208-24-010220 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,354

SEC source: 0001225208-24-010155 · doc4.xml · nonDerivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,398

SEC source: 0001225208-24-009902 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,096

SEC source: 0001225208-24-009878 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,362 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-24-009878 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,706

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.324 to $87.94, inclusive. The reporting person undertakes to provide upon request bythe U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-009878 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-24-009728 · doc4.xml · derivative · entry 7

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,676 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-24-009728 · doc4.xml · derivative · entry 6

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,635

Underlying: Common Stock · 56,211 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-009728 · doc4.xml · nonDerivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,521,205

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.145 to $85.12, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-009728 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,681,387

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.14 to $85.20, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-009728 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,683,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

SEC source: 0001225208-24-009728 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,628,307

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

SEC source: 0001225208-24-009605 · doc4.xml · derivative · entry 5

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,380

Underlying: Common Stock · 1,197 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-24-009605 · doc4.xml · derivative · entry 4

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,066

Underlying: Common Stock · 3,066 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-009605 · doc4.xml · nonDerivative · entry 3

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,028

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-009605 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,011

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-009605 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,814

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-009234 · doc4.xml · derivative · entry 7

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,676

Underlying: Common Stock · 55,675 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-24-009234 · doc4.xml · derivative · entry 6

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 224,846

Underlying: Common Stock · 56,211 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.